Skin Effects of Oestrogen in Transfeminine People

Evidence Note

What is the question?

Feminising hormone therapy raises oestrogen — almost always 17β-oestradiol — while lowering testosterone. Both hormones act on skin, so what people experience is the combined effect, not oestrogen alone. This note asks a practical question across the changes people notice most — less oily skin, acne, dryness, thickness and “glow”, wound healing, and facial pigmentation: what does the evidence actually support, and how good is it?

What does the evidence say?

The clearest change is that skin becomes less oily. Sebum production is driven by androgens, so lowering testosterone lowers it — the best-supported skin effect of feminising therapy, and the reason acne often improves. That improvement is real but less certain than the acne flare testosterone causes in trans men, and acne has several causes beyond oil. With less surface oil, some people find their skin tips the other way, towards dryness.

Beyond oil, the picture is mostly borrowed. In cisgender menopausal women, oestrogen increases skin collagen and thickness, improves hydration, and speeds wound healing — the last shown even in elderly men. But these effects have barely been measured in trans women, and skin thickness is genuinely complicated: feminising therapy adds oestrogen, which builds collagen, while removing the androgens that had been thickening the skin, so the net result is unknown. The one place oestrogen may make skin worse is pigmentation: it is one of the hormonal drivers of melasma, the patchy facial darkening also triggered by pregnancy and the combined pill.

How strong is the evidence?

Weak, and mostly indirect. The single largest study of skin changes in trans people measured mainly acne and hair, and its clearest findings were in trans men. The reduced-sebum finding rests on small, older trans studies; nearly everything else is extrapolated from cisgender menopause and hormone-replacement research, often using oestrogens and routes unlike modern therapy. Almost none of the trans-specific evidence uses objective skin measurements. The overall certainty for trans women is low — not because the biology is implausible, but because it has so rarely been measured in the people this note is about.

Where are the uncertainties?

The big ones are simple to state. No one has directly measured the net effect on trans women’s skin thickness. No one knows how much of the reduced oiliness and improved acne is the oestrogen versus the anti-androgen. There are no reliable figures for how common melasma is on feminising therapy, or whether dose, route or an added progestogen change any skin outcome. And there is almost no objective-endpoint data of any kind.

What oestrogen does to skin is well measured — in cisgender women. In trans women, it is mostly still unknown.

That gap, between a plausible direction and a measured effect, is the thing to carry into any expectation about skin.

What does this mean for practice?

This is a summary, not a skincare or prescribing guide, and none of it is a reason to change how hormones are taken. But a few things are well enough supported to say plainly. Expect skin to become less oily, and acne often to improve; be ready for the opposite, in the form of dryness, which a plain moisturiser handles. Do not expect reliable “rejuvenation” — the collagen and thickness gains seen in menopausal women have not been shown to transfer to trans women. Take pigmentation seriously: for anyone prone to melasma or with darker skin, daily broad-spectrum and, ideally, tinted (iron-oxide) sunscreen is the single most useful step, because visible light matters here as much as ultraviolet. And treat any new facial pigmentation as something to show a clinician, since it has causes other than hormones.